MCID: ENC004
MIFTS: 61

Encephalitis

Categories: Ear diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Encephalitis

MalaCards integrated aliases for Encephalitis:

Name: Encephalitis 12 74 53 58 29 54 6 42 44 15 71

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:9588
MeSH 44 D004660
NCIt 50 C26760
SNOMED-CT 67 267682000
MESH via Orphanet 45 D004660
UMLS via Orphanet 72 C0014038
Orphanet 58 ORPHA97275
UMLS 71 C0014038

Summaries for Encephalitis

NINDS : 53 Meningitis is an infection of the meninges, the membranes that surround the brain and spinal cord. Encephalitis is inflammation of the brain itself. Anyone can get encephalitis or meningitis. Causes of encephalitis and meningitis include viruses, bacteria, fungus, and parasites. Anyone experiencing symptoms of meningitis or encephalitis should see a doctor immediately. Symptoms of encephalitis that might require emergency treatment include loss of consciousness, seizures, muscle weakness, or sudden severe dementia. Other symptoms include: sudden fever, headache, vomiting, heightened sensitivity to light, stiff neck and back, confusion and impaired judgment, drowsiness, weak muscles, a clumsy and unsteady gait, irritability. In more severe cases, people may have problems with speech or hearing, vision problems, and hallucinations. Symptoms of meningitis, which may appear suddenly, often include: high fever, severe and persistent headache, stiff neck, nausea, sensitivity to bright light, vomiting, and changes in behavior such as confusion, sleepiness, and difficulty waking up. In infants, symptoms of meningitis or encephalitis may include fever, vomiting, lethargy, body stiffness, unexplained irritability, and a full or bulging fontanel (the soft spot on the top of the head).

MalaCards based summary : Encephalitis is related to herpes simplex encephalitis and tick-borne encephalitis, and has symptoms including seizures, tremor and back pain. An important gene associated with Encephalitis is UNC93B1 (Unc-93 Homolog B1, TLR Signaling Regulator), and among its related pathways/superpathways are Innate Immune System and Viral mRNA Translation. The drugs Formaldehyde and Dimenhydrinate have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and temporal lobe, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A brain disease that is characterized as an acute inflammation of the brain with flu-like symptoms.

MedlinePlus : 42 Encephalitis is an inflammation of the brain. Usually the cause is a viral infection, but bacteria can also cause it. It can be mild or severe. Most cases are mild. You may have flu-like symptoms. With a mild case, you may just need rest, plenty of fluids, and a pain reliever. Severe cases need immediate treatment. Symptoms of severe cases include Severe headache Sudden fever Drowsiness Vomiting Confusion Seizures In babies, additional symptoms may include constant crying, poor feeding, body stiffness, and bulging in the soft spots of the skull. Severe cases may require a stay in the hospital. Treatments include oral and intravenous (IV) medicines to reduce inflammation and treat infection. Patients with breathing difficulties may need artificial respiration. Some people may need physical, speech, and occupational therapy once the illness is under control. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 74 Encephalitis is inflammation of the brain. The severity can be variable with symptoms including... more...

Related Diseases for Encephalitis

Diseases in the Encephalitis family:

Viral Encephalitis Autoimmune Encephalitis
Chronic Encephalitis Infectious Encephalitis

Diseases related to Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1391)
# Related Disease Score Top Affiliating Genes
1 herpes simplex encephalitis 33.1 UNC93B1 TRAF3 TLR3 TICAM1 IRF3
2 tick-borne encephalitis 33.0 TLR3 RSAD2 DDX58 CXCL10 CD209 CCR5
3 viral encephalitis 33.0 UNC93B1 TLR3 IL1B CXCL10 CCL2
4 japanese encephalitis 32.7 TRIM52 TLR3 SPCS1 RSAD2 IRF3 DDX58
5 west nile encephalitis 32.5 CLEC4M CCR5
6 venezuelan equine encephalitis 32.5 RPSA PPP1CA DDX3X DDX1 CXCL10 CCL2
7 acute necrotizing encephalitis 32.5 UNC93B1 TLR3
8 west nile virus 32.4 SPCS1 RSAD2 IRF3 DDX58 CLEC4M CD209
9 herpes simplex 32.2 UNC93B1 TRAF3 TLR3 TICAM1 IRF3 DDX58
10 rubella 32.0 TLR3 IL1B DDX58
11 aicardi-goutieres syndrome 32.0 UNC93B1 TLR3 RSAD2 IRF3 DDX58 CXCL10
12 zika fever 31.9 TLR3 DDX58 CD209
13 west nile fever 31.9 IRF3 CXCL10 CLEC4M CD209 CCR5
14 lymphocytic choriomeningitis 31.9 IRF3 DDX58 DDX3X CD209
15 measles 31.8 TLR3 IRF3 IL1B DDX58 CD209
16 influenza 31.7 TLR3 RSAD2 IRF3 IL1B DDX58 CXCL10
17 mumps 31.6 TLR3 IL1B CXCL10
18 rabies 31.6 TLR3 IRF3 DDX58 CXCL10
19 dengue virus 31.5 SPCS1 RSAD2 RPSA DDX58 CD209
20 disease by infectious agent 31.3 IL1B CLEC4M CD209 CCR5
21 immune deficiency disease 31.2 IL1B CXCL10 CLEC4M CD209 CCR5 CCL2
22 neuritis 31.2 IL1B CXCL10 CCR5 CCL2
23 west nile virus infection 31.2 IRF3 CCR5
24 optic neuritis 31.1 IL1B CXCL10 CCR5
25 yellow fever 31.1 SPCS1 RSAD2 IL1B DDX58 CXCL10 CCR5
26 chikungunya 31.1 RSAD2 IL1B DDX58 CD209 CCL2
27 stomatitis 31.0 RSAD2 IL1B DDX58
28 human immunodeficiency virus type 1 31.0 TLR3 IRF3 CXCL10 CLEC4M CD209 CCR5
29 pneumonia 31.0 TLR3 IL1B CXCL10 CCL2
30 hepatitis a 30.9 TLR3 TICAM1 IL1B
31 myocarditis 30.8 TLR3 IL1B CCL2 ABCD1
32 uveitis 30.8 IL1B CXCL10 CCR5 CCL2
33 pertussis 30.8 TICAM1 IL1B CCL2
34 newcastle disease 30.8 TLR3 IRF3 DDX58 CXCL10
35 demyelinating disease 30.7 IL1B CXCL10 CCL2 ABCD1
36 dengue shock syndrome 30.7 IL1B CLEC4M CD209 CCL2
37 trypanosomiasis 30.7 IL1B CXCL10 CCL2
38 avian influenza 30.6 DDX58 CXCL10 CCR5
39 severe acute respiratory syndrome 30.6 TRAF3 IRF3 IL1B DDX58 CXCL10 CLEC4M
40 covid-19 30.5 IL1B CXCL10 CCL2
41 viral infectious disease 30.5 TLR3 IRF3 IL1B DDX58 CXCL10 CLEC4M
42 aspergillosis 30.5 TLR3 IL1B CXCL10 CD209
43 sarcoidosis 1 30.5 IL1B CXCL10 CCR5 CCL2
44 plague 30.5 IL1B DDX58 CCR5
45 proteasome-associated autoinflammatory syndrome 1 30.4 IL1B CXCL10 CCL2
46 pyelonephritis 30.4 IL1B CXCL10 CCL2
47 bronchiolitis 30.3 TLR3 IL1B CXCL10 CCL2
48 bronchitis 30.3 IL1B DDX1 CXCL10
49 hepatitis 30.3 TICAM1 RSAD2 IRF3 DDX58 DDX3X CXCL10
50 viral pneumonia 30.3 TLR3 DDX58 CXCL10

Graphical network of the top 20 diseases related to Encephalitis:



Diseases related to Encephalitis

Symptoms & Phenotypes for Encephalitis

UMLS symptoms related to Encephalitis:


seizures, tremor, back pain, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Encephalitis according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.03 RPSA
2 Decreased viability GR00221-A-1 10.03 CCL2
3 Decreased viability GR00221-A-4 10.03 CCL2
4 Decreased viability GR00240-S-1 10.03 RPSA
5 Decreased viability GR00249-S 10.03 DDX1 IL1B RPSA TICAM1 TLR3 TRAF3
6 Decreased viability GR00342-S-1 10.03 TLR3
7 Decreased viability GR00342-S-2 10.03 TLR3
8 Decreased viability GR00381-A-1 10.03 RPSA
9 Decreased viability GR00386-A-1 10.03 CCL2 CLEC4M IL1B UNC93B1
10 Decreased viability GR00402-S-2 10.03 ABCD1 CCL2 RPSA SPCS1 TICAM1 TLR3
11 Increased the percentage of infected cells GR00402-S-1 8.32 TLR3

MGI Mouse Phenotypes related to Encephalitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 ABCD1 CCR5 CD209 CLEC4M CXCL10 DDX58
2 homeostasis/metabolism MP:0005376 10 ABCD1 CCR5 CD209 CLEC4M CXCL10 DDX3X
3 immune system MP:0005387 9.77 ABCD1 CCL2 CCR5 CLEC4M CXCL10 DDX58
4 mortality/aging MP:0010768 9.44 ABCD1 CCR5 CLEC4M CXCL10 DDX1 DDX3X

Drugs & Therapeutics for Encephalitis

Drugs for Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
2
Dimenhydrinate Approved Phase 4 523-87-5 441281
3
Lactitol Approved, Investigational Phase 4 585-86-4 157355
4
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
5
Sulfamethoxazole Approved Phase 4 723-46-6 5329
6
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
7
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
8
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
11
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
12 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
13
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
14
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
17
Polygeline Experimental Phase 4 66455-30-9
18
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
19 Hematinics Phase 4
20 Epoetin alfa Phase 4 113427-24-0
21 Antibodies, Blocking Phase 4
22 Disinfectants Phase 4
23 Anti-Bacterial Agents Phase 4
24 Antiparasitic Agents Phase 4
25 Antiprotozoal Agents Phase 4
26 Antimalarials Phase 4
27 Vitamin B Complex Phase 4
28 Folic Acid Antagonists Phase 4
29 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
30 Vitamin B9 Phase 4
31 Folate Phase 4
32 Vaccines Phase 4
33 Antiemetics Phase 4
34 Protective Agents Phase 4
35 Gastrointestinal Agents Phase 4
36 Anti-Inflammatory Agents Phase 4
37 Hormone Antagonists Phase 4
38 Methylprednisolone Acetate Phase 4
39 Hormones Phase 4
40 glucocorticoids Phase 4
41 Neuroprotective Agents Phase 4
42 Antineoplastic Agents, Hormonal Phase 4
43
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
44 Orange Approved Phase 3
45
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
46
Acyclovir Approved Phase 3 59277-89-3 2022
47 Insect Repellents Phase 3
48 Calcineurin Inhibitors Phase 2, Phase 3
49 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
50 valacyclovir Phase 3

Interventional clinical trials:

(show top 50) (show all 224)
# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
2 Assessment of Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV Unknown status NCT01954810 Phase 4
3 Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Unknown status NCT03004209 Phase 4 Erythropoietin
4 A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Non-inferiority With Respect to an Earlier Product. Completed NCT01567865 Phase 4
5 TBE (Tick-borne Encephalitis ) Vaccination in Allergic Patients Completed NCT02511535 Phase 4
6 Neutralizing Antibody Titers 6 Years After the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection Completed NCT02039440 Phase 4
7 An Open-label, Uncontrolled Phase 4 Study to Assess the Safety and Immunogenicity of the Japanese Encephalitis (JE) Vaccine Ixiaro® (IC51) in an Elderly Population Completed NCT01158599 Phase 4
8 Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka Completed NCT00463684 Phase 4
9 Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka Completed NCT00463476 Phase 4
10 A Phase IV, Uncontrolled, Open-Label, Multi-Center Study in Children and Adolescents: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New Pediatric TBE Vaccine (Free of Protein-Derived Stabilizer) in Study V48P4E1, Five Years After First Booster Immunization Completed NCT00452621 Phase 4
11 A Phase IV, Randomized, Open-Label, Multi-Center Study in Adults: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer) in Study V48P2E1, 5 Years After First Booster Immunization and Evaluation of Booster Kinetics in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer), 5 Years After First Booster Immunization Completed NCT00311493 Phase 4
12 A Phase IV, Randomized, Controlled, Single-Blind, Multi-Center Study in Children to Evaluate the Safety, Tolerability and Immunogenicity of Two TBE Vaccines Administered According to Two Different Schedules. Completed NCT00311441 Phase 4
13 Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225) Completed NCT00163540 Phase 4
14 A Study to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Completed NCT01815073 Phase 4
15 A Multi-center, Open, phase4 Study to Assess the Long-term Immunogenicity and Safety of Fourth Administration of BR JEV and to Investigate on Vaccine Interchangeability in Children Aged 6 Years Who Received 3 Doses With ENCEVAC or JEV-GCC Completed NCT02532569 Phase 4
16 Characterisation of Cellular and Humoral Immunity in Elderly People After Immunization With a Purified, Inactivated Japanese Encephalitis Vaccine. Completed NCT01398540 Phase 4
17 A Phase IV, Open-label, Multi-center Follow-up Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Completed NCT01106482 Phase 4
18 Open-label Follow-up Study to Investigate the Seropersistence of TBE Antibodies and the Booster Response to a Tick-borne Encephalitis Vaccine in Children and Adolescents Aged 3 - 18 Years Completed NCT00161967 Phase 4
19 Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years Completed NCT00161954 Phase 4
20 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Completed NCT00161785 Phase 4
21 Immunogenicity of Co-administration of Measles Containing Vaccine and Japanese Encephalitis Alive Vaccines Completed NCT02643433 Phase 4
22 Post-licensure, Phase IV, Safety Study of IMOJEV® in Thailand Completed NCT01981967 Phase 4
23 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
24 Assessment of Long Term Immunogenicity of Japanese Encephalitis Live Attenuated SA-14-14-2 Vaccine in Previously Vaccinated Bangladeshi Children and Antibody Response and Safety to a Booster Dose Completed NCT02514746 Phase 4
25 Open-label Phase IV Study to Investigate the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults (Follow Up to Study 223) Completed NCT00503529 Phase 4
26 Open-label Phase Iv Study To Investigate The Seropersistence Of Tick-borne Encephalitis (Tbe) Virus Antibodies After The First Booster And The Response To A Second Booster Vaccination With Fsme-immun In Children, Adolescents And Young Adults (Follow-up To Study 700401) Completed NCT00894686 Phase 4
27 A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 Completed NCT01656200 Phase 4
28 Open-label Phase 4 Study to Investigate the Seropersistence of Tick-borne Encephalitis (TBE) Virus Antibodies From 7 to 10 Years After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults Completed NCT01582698 Phase 4
29 Phase 4 Clinical Trial of Cervico-vaginal Immune Responses Following Three Right Deltoid or Right Thigh Intramuscular Immunisations With TicoVac (Tick Borne Encephalitis Virus [TBEV]) Vaccine in Adult Female Participants Completed NCT01710189 Phase 4 TicoVac
30 A Phase IV, Open-label, Single-center Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
31 Characterization of Humoral and Cellular Immunity of Low and High-responders After TBE Vaccination Completed NCT00804219 Phase 4
32 Pyrimethamine Plus Sulfadiazine Versus Trimethoprim Plus Sulfamethoxazole for Treatment of Toxoplasmic Encephalitis in AIDS Patients: A Randomized Controlled Trial. Completed NCT00367081 Phase 4 TMX-SMX (Bactrim(R));Pyrimethamine plus Sulfadiazine plus leucoverin
33 Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine (IMOJEV) as a Booster Dose After a Primary Vaccination With CD.JEVAX in Thai Children Completed NCT02526550 Phase 4
34 Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study) Completed NCT00461695 Phase 4
35 A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Manufactured in a New Good Manufacturing Practices Facility and Non-inferiority With Respect to an Earlier Product. Completed NCT01635816 Phase 4
36 A Phase IV, Uncontrolled, Open-label, Single-center Study in Adolescents and Adults: Evaluation of Immunogenicity and Safety of the First Booster Immunization With Novartis' TBE Vaccine for Adults in Participants of Study V48P7 and Long-term Evaluation of Immunogenicity up to 5 Years After First Booster Immunization Completed NCT00387634 Phase 4
37 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
38 Characterisation of Cellular and Humoral Immune Responses Following the First Booster Immunisation With the Inactivated, Purified Japanese Encephalitis Vaccine IXIARO® in Elderly Compared to Young Individuals. Recruiting NCT03971058 Phase 4
39 Application of a TBE-Vaccine in Obese Persons Active, not recruiting NCT04017052 Phase 4 FSME-IMMUN Vaccine
40 Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Active, not recruiting NCT03294135 Phase 4
41 Primary TBE Vaccination for the Elderly Not yet recruiting NCT04573205 Phase 4 FSME-IMMUN Vaccine
42 Low Dose Versus High Dose Steroids in Treatment of Viral Encephalitis Not yet recruiting NCT04103684 Phase 4 Methylprednisolone;Dexamethasone
43 A Phase III Multi-centre Randomised, Double Blind, Placebo Controlled Trial to Assess the Role of Intravenous Immunoglobulin in the Management of Children With Encephalitis Unknown status NCT02308982 Phase 3 Immunoglobulins, Intravenous (Privigen);Placebo
44 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets Against Malaria, JE & Dengue in Rural Communities in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
45 Efficacy of Tacrolimus and i.v.-Immunoglobulins in Rasmussen Encephalitis With Start of Treatment in the Acute Disease Stage. Prospective, Randomised, Open Parallel Group Study Unknown status NCT00545493 Phase 2, Phase 3 Tacrolimus;i.v. immunoglobulins
46 B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment. Unknown status NCT02229942 Phase 3 Rituximab;Placebo
47 A Single-centre Phase III Clinical Trial for Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Produced by Shandong Hengye Biotech Co., Ltd. in Healthy Chinese Infants Aged 6-11 Months, Aimed to Evaluate Immunogenicity and Safety Completed NCT02367664 Phase 3
48 Assessment of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine Given Alone Completed NCT00249769 Phase 3
49 Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses? Completed NCT01361776 Phase 2, Phase 3
50 Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study. Completed NCT00595465 Phase 3

Search NIH Clinical Center for Encephalitis

Cochrane evidence based reviews: encephalitis

Genetic Tests for Encephalitis

Genetic tests related to Encephalitis:

# Genetic test Affiliating Genes
1 Encephalitis 29

Anatomical Context for Encephalitis

MalaCards organs/tissues related to Encephalitis:

40
T Cells, Brain, Temporal Lobe, Bone Marrow, Spinal Cord, Kidney, Cortex

Publications for Encephalitis

Articles related to Encephalitis:

(show top 50) (show all 30038)
# Title Authors PMID Year
1
50 Years Ago in TheJournalofPediatrics: Herpes Simplex Encephalitis: No Longer a Brain-Teaser. 42 61
33342503 2021
2
Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy. 42
33361386 2021
3
The management of neuropsychiatric lupus in the 21st century: still so many unmet needs? 42
33280014 2020
4
Cytokines and chemokines in viral encephalitis: a clinicoradiological correlation. 54 61
20153811 2010
5
Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. 54 61
19200759 2009
6
Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. 61 54
18710325 2008
7
Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. 54 61
18782012 2008
8
CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. 61 54
18678898 2008
9
Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. 61 54
18501510 2008
10
Increased expression of monocyte CD44v6 correlates with the deveopment of encephalitis in rhesus macaques infected with simian immunodeficiency virus. 54 61
18471064 2008
11
A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. 61 54
18179389 2008
12
Activated macrophages in HIV encephalitis and a macaque model show increased [3H](R)-PK11195 binding in a PI3-kinase-dependent manner. 61 54
17888571 2007
13
An interferon-gamma-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. 61 54
17240458 2007
14
Aquaporin 4 regulation during acute and long-term experimental Herpes simplex virus encephalitis. 54 61
17454447 2007
15
CD45 isoform expression in microglia and inflammatory cells in HIV-1 encephalitis. 61 54
17107594 2006
16
Viral risk factor for seizures: pathobiology of dynorphin in herpes simplex viral (HSV-1) seizures in an animal model. 54 61
16843674 2006
17
Kappa opioid control of seizures produced by a virus in an animal model. 61 54
16399805 2006
18
Elevated concentration of the chemokine CCL3 (MIP-1alpha) in cerebrospinal fluid and serum of patients with tick borne encephalitis. 61 54
17357337 2006
19
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. 54 61
15961516 2005
20
[Serum and cerebrospinal concentrations of sICAM-1 sICAM-2, sICAM-3 in neuroborrellosis and tick borne encephalitis--preliminary report]. 61 54
16245421 2005
21
Neuroprotective and anti-human immunodeficiency virus activity of minocycline. 54 61
15855434 2005
22
Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. 54 61
15558055 2004
23
Investigations on four host response factors whose expression is enhanced in X4 SHIV encephalitis. 61 54
15579283 2004
24
Neuronal apoptosis is mediated by CXCL10 overexpression in simian human immunodeficiency virus encephalitis. 54 61
15111302 2004
25
Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. 61 54
14739339 2004
26
Evaluation of antioxidant status in children with acute bacterial meningitis and encephalitis. 61 54
14585750 2003
27
Maedi-visna virus and caprine arthritis encephalitis virus genomes encode a Vpr-like but no Tat protein. 61 54
12915575 2003
28
Expression of the interferon-induced MxA protein in viral encephalitis. 54 61
12787324 2003
29
Lack of trans-activation function for Maedi Visna virus and Caprine arthritis encephalitis virus Tat proteins. 61 54
12667801 2003
30
Elevated peripheral benzodiazepine receptor expression in simian immunodeficiency virus encephalitis. 61 54
12587072 2003
31
Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat. 61 54
12605891 2003
32
The Tat protein of the caprine arthritis encephalitis virus interacts with the Notch2 EGF-like repeats and the epithelin/granulin precursor. 61 54
12931033 2003
33
A novel simian immunodeficiency virus model that provides insight into mechanisms of human immunodeficiency virus central nervous system disease. 61 54
12491150 2002
34
Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. 54 61
12095987 2002
35
Serum time course of two brain-specific proteins, alpha(1) brain globulin and neuron-specific enolase, in tick-born encephalitis and Lyme disease. 54 61
11983209 2002
36
Cell cycle proteins exhibit altered expression patterns in lentiviral-associated encephalitis. 54 61
11896158 2002
37
Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. 54 61
12162592 2002
38
Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. 61 54
11574916 2001
39
Role of CD23 in astrocytes inflammatory reaction during HIV-1 related encephalitis. 61 54
11500085 2001
40
Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. 61 54
11282169 2001
41
[Diagnostic and prognostic significance of the antibodies to the myelin basic protein in acute neuroinfections in children]. 54 61
11209527 2001
42
Blood-brain barrier disruption in simian immunodeficiency virus encephalitis. 61 54
11054186 2000
43
Induction of cell-cycle regulators in simian immunodeficiency virus encephalitis. 61 54
10934153 2000
44
Elevated cerebrospinal fluid level of ciliary neurotrophic factor in acute disseminated encephalomyelitis. 61 54
10980311 2000
45
Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. 54 61
10665489 2000
46
Up-regulation of the hyaluronate receptor CD44 in canine distemper demyelinated plaques. 54 61
10672320 2000
47
Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. 54 61
10640747 2000
48
Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. 54 61
10595922 1999
49
Absence of brain-derived neurotrophic factor and trkB receptor immunoreactivity in glia of Alzheimer's disease. 61 54
10502038 1999
50
Characterization of the inflammatory response during acute measles encephalitis in NSE-CD46 transgenic mice. 54 61
10337919 1999

Variations for Encephalitis

ClinVar genetic disease variations for Encephalitis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ABCD1 NM_000033.4(ABCD1):c.1866-1G>C SNV Likely pathogenic 523312 rs1557055311 X:153008674-153008674 X:153743220-153743220

Expression for Encephalitis

Search GEO for disease gene expression data for Encephalitis.

Pathways for Encephalitis

Pathways related to Encephalitis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 UNC93B1 TRAF3 TLR3 TICAM1 RSAD2 IRF3
2
Show member pathways
13.7 TRAF3 TLR3 SPCS1 RPSA IRF3 IL1B
3
Show member pathways
13.22 TRAF3 RSAD2 IRF3 IL1B DDX58 CXCL10
4
Show member pathways
12.78 TRAF3 TLR3 TICAM1 IRF3 IL1B CCR5
5
Show member pathways
12.74 TRAF3 TLR3 TICAM1 RSAD2 IRF3 IL1B
6
Show member pathways
12.59 TRAF3 TLR3 TICAM1 IRF3 IL1B
7 12.56 TRAF3 TLR3 TICAM1 PPP1CA IRF3 IL1B
8
Show member pathways
12.42 TRAF3 IRF3 DDX58 DDX3X CXCL10
9
Show member pathways
12.35 TLR3 TICAM1 IRF3 IL1B DDX58 CXCL10
10
Show member pathways
12.21 TRAF3 IL1B CXCL10 CCL2
11
Show member pathways
12.19 TLR3 TICAM1 IRF3 IL1B
12 12.18 TRAF3 IRF3 DDX3X CCR5
13
Show member pathways
12.13 TRAF3 TLR3 TICAM1 IRF3
14 12.12 TRAF3 TLR3 TICAM1 RSAD2 IRF3 IL1B
15
Show member pathways
12.07 TRAF3 TLR3 TICAM1 RSAD2 IRF3 IL1B
16 12.06 TRAF3 TICAM1 IRF3 IL1B CCL2
17 11.97 TICAM1 IRF3 IL1B CCL2
18 11.84 TRAF3 IL1B CXCL10 CCL2
19 11.8 TRAF3 TICAM1 IL1B DDX58
20 11.64 TICAM1 IRF3 IL1B
21 11.31 IL1B CXCL10 CCR5 CCL2
22 10.8 IL1B CCL2

GO Terms for Encephalitis

Cellular components related to Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 TRIM52 TRAF3 TLR3 TICAM1 RPSA PPP1CA

Biological processes related to Encephalitis according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.06 TLR3 TICAM1 IL1B DDX58 DDX3X
2 immune response GO:0006955 10.06 TLR3 IL1B CXCL10 CCR5 CCL2
3 inflammatory response GO:0006954 10.03 TLR3 TICAM1 IL1B CXCL10 CCR5 CCL2
4 immune system process GO:0002376 10 UNC93B1 TRAF3 TLR3 TICAM1 RSAD2 IRF3
5 cytokine-mediated signaling pathway GO:0019221 9.98 IL1B CXCL10 CCR5 CCL2
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.95 TRIM52 TLR3 TICAM1 IRF3 DDX1
7 response to lipopolysaccharide GO:0032496 9.91 TICAM1 IRF3 IL1B CXCL10
8 cellular response to lipopolysaccharide GO:0071222 9.91 TICAM1 IRF3 IL1B CXCL10 CCR5 CCL2
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.9 TRIM52 TLR3 TICAM1 IL1B
10 innate immune response GO:0045087 9.9 UNC93B1 TRAF3 TLR3 TICAM1 RSAD2 IRF3
11 positive regulation of interleukin-6 production GO:0032755 9.88 TLR3 TICAM1 IL1B DDX58
12 response to virus GO:0009615 9.88 TLR3 RSAD2 DDX58 DDX3X DDX1 CXCL10
13 positive regulation of DNA-binding transcription factor activity GO:0051091 9.86 TRIM52 IL1B DDX58
14 viral entry into host cell GO:0046718 9.85 RPSA CLEC4M CD209
15 positive regulation of tumor necrosis factor production GO:0032760 9.85 TLR3 TICAM1 DDX58
16 positive regulation of JNK cascade GO:0046330 9.85 TRAF3 TLR3 IL1B
17 chemokine-mediated signaling pathway GO:0070098 9.83 CXCL10 CCR5 CCL2
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 TLR3 IL1B DDX3X
19 positive regulation of interleukin-8 production GO:0032757 9.81 TLR3 IL1B DDX58
20 positive regulation of type I interferon production GO:0032481 9.81 TLR3 TICAM1 IRF3
21 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TICAM1 IRF3 IL1B CCL2
22 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.78 TRAF3 TLR3 TICAM1 IRF3
23 toll-like receptor signaling pathway GO:0002224 9.77 UNC93B1 TRAF3 TLR3
24 positive regulation of interferon-beta production GO:0032728 9.77 TLR3 TICAM1 IRF3 DDX58 DDX3X
25 positive regulation of interferon-alpha production GO:0032727 9.76 TLR3 IRF3 DDX58 DDX3X
26 cellular response to exogenous dsRNA GO:0071360 9.74 TLR3 IRF3 DDX58
27 response to exogenous dsRNA GO:0043330 9.72 TLR3 TICAM1 IRF3 DDX58 DDX1
28 viral genome replication GO:0019079 9.71 CLEC4M CD209 CCL2
29 toll-like receptor 3 signaling pathway GO:0034138 9.7 UNC93B1 TLR3 TICAM1
30 viral process GO:0016032 9.7 TICAM1 RSAD2 RPSA PPP1CA IRF3 DDX58
31 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.69 TICAM1 DDX58 DDX1
32 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.68 IL1B DDX58
33 modulation by virus of host morphology or physiology GO:0019048 9.65 CLEC4M CD209
34 protein localization to cytoplasmic stress granule GO:1903608 9.65 DDX3X DDX1
35 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.64 TLR3 TICAM1
36 positive regulation of toll-like receptor 7 signaling pathway GO:0034157 9.63 RSAD2 DDX3X
37 cell-cell recognition GO:0009988 9.62 CLEC4M CD209
38 detection of virus GO:0009597 9.62 TLR3 DDX58
39 virion attachment to host cell GO:0019062 9.61 CLEC4M CD209
40 peptide antigen transport GO:0046968 9.58 CLEC4M CD209
41 defense response to virus GO:0051607 9.28 UNC93B1 TRIM52 TLR3 TICAM1 RSAD2 IRF3

Molecular functions related to Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 UNC93B1 TRAF3 TLR3 TICAM1 SPCS1 RSAD2
2 RNA helicase activity GO:0003724 9.33 DDX58 DDX3X DDX1
3 virion binding GO:0046790 9.32 CLEC4M CD209
4 double-stranded RNA binding GO:0003725 9.13 TLR3 DDX58 DDX1
5 virus receptor activity GO:0001618 8.92 RPSA CLEC4M CD209 CCR5

Sources for Encephalitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....